BMO Capital Downgrades Globus Medical to Market Perform, Lowers Price Target to $78

Benzinga · 2d ago
BMO Capital analyst Vik Chopra downgrades Globus Medical (NYSE:GMED) from Outperform to Market Perform and lowers the price target from $94 to $78.